Class information for:
Level 1: CHEMOTHERAPY INDUCED ANEMIA//EPOETIN ALFA//CHEMOTHERAPY INDUCED ANAEMIA

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
5322 1571 37.1 79%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
875 10801 ERYTHROPOIETIN//DARBEPOETIN ALFA//ANEMIA

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CHEMOTHERAPY INDUCED ANEMIA Author keyword 89 90% 2% 38
2 EPOETIN ALFA Author keyword 53 40% 6% 102
3 CHEMOTHERAPY INDUCED ANAEMIA Author keyword 49 94% 1% 17
4 DARBEPOETIN ALFA Author keyword 35 34% 5% 83
5 EPOETIN BETA Author keyword 23 42% 3% 41
6 ERYTHROPOIESIS STIMULATING AGENTS Author keyword 22 29% 4% 65
7 ERYTHROPOIETIN RECEPTOR Author keyword 17 23% 4% 67
8 CANCER RELATED ANEMIA Author keyword 17 75% 1% 12
9 CANCER RELATED ANAEMIA Author keyword 14 100% 0% 7
10 ERYTHROPOIETIC PROTEINS Author keyword 14 100% 0% 7

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CHEMOTHERAPY INDUCED ANEMIA 89 90% 2% 38 Search CHEMOTHERAPY+INDUCED+ANEMIA Search CHEMOTHERAPY+INDUCED+ANEMIA
2 EPOETIN ALFA 53 40% 6% 102 Search EPOETIN+ALFA Search EPOETIN+ALFA
3 CHEMOTHERAPY INDUCED ANAEMIA 49 94% 1% 17 Search CHEMOTHERAPY+INDUCED+ANAEMIA Search CHEMOTHERAPY+INDUCED+ANAEMIA
4 DARBEPOETIN ALFA 35 34% 5% 83 Search DARBEPOETIN+ALFA Search DARBEPOETIN+ALFA
5 EPOETIN BETA 23 42% 3% 41 Search EPOETIN+BETA Search EPOETIN+BETA
6 ERYTHROPOIESIS STIMULATING AGENTS 22 29% 4% 65 Search ERYTHROPOIESIS+STIMULATING+AGENTS Search ERYTHROPOIESIS+STIMULATING+AGENTS
7 ERYTHROPOIETIN RECEPTOR 17 23% 4% 67 Search ERYTHROPOIETIN+RECEPTOR Search ERYTHROPOIETIN+RECEPTOR
8 CANCER RELATED ANEMIA 17 75% 1% 12 Search CANCER+RELATED+ANEMIA Search CANCER+RELATED+ANEMIA
9 CANCER RELATED ANAEMIA 14 100% 0% 7 Search CANCER+RELATED+ANAEMIA Search CANCER+RELATED+ANAEMIA
10 ERYTHROPOIETIC PROTEINS 14 100% 0% 7 Search ERYTHROPOIETIC+PROTEINS Search ERYTHROPOIETIC+PROTEINS

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 COMMUNITY ONCOLOGY 250 71% 13% 204
2 CHEMOTHERAPY INDUCED ANEMIA 247 75% 11% 180
3 EPOETIN ALPHA 146 33% 23% 362
4 RECEIVING NONPLATINUM CHEMOTHERAPY 128 86% 4% 66
5 WEEKS ALLEVIATES ANEMIA 120 89% 4% 55
6 CISPLATIN ASSOCIATED ANEMIA 97 90% 3% 43
7 RECOMBINANT HUMAN ERYTHROPOIETIN 64 11% 35% 556
8 DARBEPOETIN ALPHA 60 28% 12% 187
9 LYMPHOPROLIFERATIVE MALIGNANCIES 57 79% 2% 37
10 INCREASES HEMOGLOBIN 56 85% 2% 29

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia 2008 347 47 91%
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update 2007 177 41 80%
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes 2010 93 80 85%
American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer 2010 67 43 84%
Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials 2013 15 29 79%
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology American Society of Clinical Oncology clinical practice guideline update 2008 88 26 85%
Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data 2014 6 78 79%
Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer 2012 32 91 63%
A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment 2007 85 240 75%
Cancer- and Chemotherapy-Induced Anemia 2012 24 61 62%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 P ONCOL UNIT PULMONOL 6 38% 0.8% 13
2 AFDELING ONCOL HEMATOL 6 100% 0.3% 4
3 MULTIDISCIPLINAIRE ONCOL 5 39% 0.7% 11
4 JOAN KARNELL CANC 3 26% 0.6% 10
5 BREAST CARE SIDNEY KIMMEL CANC 2 67% 0.1% 2
6 GERIATR NURSING CLIN 2 50% 0.2% 3
7 MOL CELLULAR IMMUNOMORPHOL BASES ONCOHEMATO 2 50% 0.2% 3
8 ORTHO BIOTECH 2 40% 0.3% 4
9 ZENTRUM ONKOL HAMATOL 1 31% 0.3% 4
10 CANC SERV CLIN HAEMATOL 1 50% 0.1% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000117921 ERYTHROPOIETIN//CELLULAR MOL CEREBRAL I EMIA//CARBAMYLATED ERYTHROPOIETIN
2 0.0000117373 ANTIANEMIC AGENTS//CAS 11096 26 7//RECOMBINANT HUMAN ERYTHROPOIETIN RHEPO
3 0.0000095887 SOLUBLE TRANSFERRIN RECEPTOR//SERUM TRANSFERRIN RECEPTOR//ANEMIA OF CHRONIC DISORDERS
4 0.0000093520 ERYTHROPOIETIN//DARBEPOETIN ALFA//RENAL ANEMIA
5 0.0000085058 LEUKOFILTRATION//LEUKOREDUCTION//WHITE BLOOD CELL REDUCTION
6 0.0000084159 ERYTHROPOIETIN RECEPTOR//STEM PROGENITOR CELL BIOL PROGRAM//ERYTHROBLAST MACROPHAGE PROTEIN
7 0.0000074760 CANCER RELATED FATIGUE//SYMPTOM CLUSTER//SYMPTOM CLUSTERS
8 0.0000068936 CARBOGEN//TUMOR HYPOXIA//TUMOR OXYGENATION
9 0.0000062307 IRON SUCROSE//INTRAVENOUS IRON//IRON DEXTRAN
10 0.0000046153 ANEMIA IN THE ELDERLY//ANEMIA IN ELDERLY//ANEMIA OF CHRONIC INFLAMMATION